Provident Financial Services(PFS)

Search documents
Endeavour Announces Positive PFS Results for Assafou Project in Côte d'Ivoire
GlobeNewswire News Room· 2024-12-11 07:00
ENDEAVOUR ANNOUNCES POSITIVE PFS RESULTS FOR ASSAFOU PROJECT IN CÔTE D’IVOIRE $1,526m NPV(5%) and IRR of 28% at $2,000/oz • 329kozpa at AISC of $892/oz over first 10 years HIGHLIGHTS: PFS confirms Assafou's potential to become a tier 1 asset for EndeavourPFS highlights 329kozpa production at AISC of $892/oz over first 10 years: 15-year mine life based on maiden reserve of 4.1Moz Robust project economics with after-tax NPV(5%) of $1,526m and IRR of 28%, at a $2,000/oz gold priceInitial capital of $734m bas ...
Provident Bank Strengthens Human Resources Team with Senior Vice President to Drive the Bank's People Development Strategy
GlobeNewswire News Room· 2024-11-21 13:00
ISELIN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Provident Bank, a leading New Jersey-based financial institution, is pleased to announce that Kim Strignile has joined the Human Resources team as Senior Vice President, HR Business Partner Director. Ms. Strignile will lead the bank’s HR Business Partner and Talent Acquisition teams, playing a pivotal role in driving its people strategy. In addition, Ms. Strignile will serve as a trusted advisor and change agent, collaborating closely with Provident’s leaders ...
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
GlobeNewswire News Room· 2024-11-11 21:05
-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) -- -- Progressing through court-administered financial restructuring process with continued interest from multiple parties EMERYVILLE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (OTC: GRTSQ), a clinical-stage biotechnolo ...
Provident Financial Services(PFS) - 2024 Q3 - Quarterly Report
2024-11-07 21:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31566 PROVIDENT FINANCIAL SERVICES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 42-1547151 (State or Other Ju ...
Provident Financial Services(PFS) - 2024 Q3 - Quarterly Results
2024-10-30 17:54
Provident Financial Services, Inc. Reports Third Quarter Earnings and Declares Quarterly Cash Dividend ISELIN, NJ, October 29, 2024 - Provident Financial Services, Inc. (NYSE:PFS) (the "Company") reported net income of $46.4 million, or $0.36 per basic and diluted share for the three months ended September 30, 2024, compared to a net loss of $11.5 million, or $0.11 per basic and diluted share, for the three months ended June 30, 2024 and net income of $28.5 million, or $0.38 per basic and diluted share, for ...
Provident Financial Services(PFS) - 2024 Q3 - Earnings Call Transcript
2024-10-30 16:35
Provident Financial Services, Inc. (NYSE:PFS) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Adriano Duarte – Investor Relations Officer Tony Labozzetta – President and Chief Executive Officer Tom Lyons – Senior Executive Vice President and Chief Financial Officer Conference Call Participants Greg Zingone – Piper Sandler Billy Young – RBC Capital Tim Switzer – KBW Manuel Navas – D.A. Davidson Operator Thank you for standing by. I would like to welcome everyone to the Prov ...
Provident Financial (PFS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2024-10-30 00:06
Provident Financial (PFS) reported $210.56 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 82.2%. EPS of $0.36 for the same period compares to $0.38 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $211.25 million, representing a surprise of -0.33%. The company delivered an EPS surprise of -21.74%, with the consensus EPS estimate being $0.46. While investors scrutinize revenue and earnings changes year-over-year and how they comp ...
Provident Financial (PFS) Lags Q3 Earnings and Revenue Estimates
ZACKS· 2024-10-29 23:20
Provident Financial (PFS) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -21.74%. A quarter ago, it was expected that this holding company for The Provident Bank would post earnings of $0.28 per share when it actually produced earnings of $0.06, delivering a surprise of -78.57%. Ove ...
Provident Financial Services, Inc. Reports Third Quarter Earnings and Declares Quarterly Cash Dividend
GlobeNewswire News Room· 2024-10-29 21:00
ISELIN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the "Company") reported net income of $46.4 million, or $0.36 per basic and diluted share for the three months ended September 30, 2024, compared to a net loss of $11.5 million, or $0.11 per basic and diluted share, for the three months ended June 30, 2024 and net income of $28.5 million, or $0.38 per basic and diluted share, for the three months ended September 30, 2023. For the nine months ended September 30, 20 ...
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
Prnewswire· 2024-10-16 11:02
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16/AK104-303). This study evaluated the efficacy of its independently developed PD1/CTLA-4 bispecific antibody, 开坦尼® (cadonilimab), in combination with or without platinum-based chemotherapy and bevacizumab, compared to placebo with platinum-based chemotherapy and bevacizumab for first ...